Beijing-based healthcare venture capital institution 3E Bioventures Capital was the biggest investor in Neural Galaxy's latest fundraiser, the Beijing-headquartered firm said on its website today. The startup is joining hands with Chinese hospitals in diagnosis and treatment tests on depression, Alzheimer's disease, Parkinson's disease, autism, and stroke, it said. The firm plans to recruit from 300 to 400 researchers, engineers, and medical personnel to conquer brain diseases as soon as possible, it added. The company got over CNY100 million in its Series pre-A round from Lightspeed China Partners and others early this year. The company is developing a brain-computer interface to measure brain activity and to detect disorders. Professor Liu Hesheng at Harvard Medical School and other experts founded Neural Galaxy in July 2019.